06 May 2018 : Animal Research
Corilagin Reduces the Frequency of Seizures and Improves Cognitive Function in a Rat Model of Chronic Epilepsy
Xue Yu1ABEF, Tao Zhou1ACD, Heng Yu1CDF, Li-ying Chang1DEF, Ling-li Wei2ABCEF*DOI: 10.12659/MSM.906509
Med Sci Monit 2018; 24: ANS2832-2840
Abstract
BACKGROUND: Worldwide, epilepsy is an important chronic neurological condition. The aim of this study was to evaluate the effects of corilagin, an ellagitannin extracted from medicinal plants, on the frequency of seizures and cognitive function in a rat model of chronic epilepsy.
MATERIAL AND METHODS: Chronic epilepsy was induced in male Wistar rats by intraperitoneal (IP) injection of pentylenetetrazol (PTZ) for 36 days. Corilagin, 10 mg/kg and 20 mg/kg, was injected IP into treated rats, 24 days before the start of PTZ treatment, until the end of the protocol. The effects of corilagin were assessed by the pattern of epileptic seizures; cognitive function was assessed using the Morris water maze (MWM) navigation test. The mechanism of action of corilagin was investigated by measuring cytokine levels and oxidative stress parameters, including reactive oxygen species (ROS) production, and carbonic anhydrase inhibitory (CAI) activity. Histological analysis of fixed brain tissue sections included cresyl violet acetate staining (Nissl staining) for Nissl substance in the neuronal cytoplasm.
RESULTS: The corilagin-treated rats, compared with the control group, showed a significantly lower rate of epileptic events, improved cognitive function, reduced level of cytokines, reduced ROS production reduced CAI activity in the brain tissues (P<0.01). Histology of the rat brain tissues study showed that corilagin treatment maintained the neuronal cellular structure and number of surviving cells compared with the control group of rats.
CONCLUSIONS: The findings of this study showed that corilagin reduced the frequency of seizures and improved the cognitive function in a rat model of chronic epilepsy.
Keywords: Cytokines, epilepsia partialis continua, Neurologic Manifestations
Editorial
01 February 2025 : Editorial
Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-SmokersDOI: 10.12659/MSM.948255
Med Sci Monit 2025; 31:e948255
In Press
Clinical Research
Immune Dysregulation in Acute Herpes Zoster: Predictive Factors for Postherpetic NeuralgiaMed Sci Monit In Press; DOI: 10.12659/MSM.944688
Clinical Research
Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal CancerMed Sci Monit In Press; DOI: 10.12659/MSM.947202
Laboratory Research
Comparison of Color Stability Between Single-Shade and Conventional Composite Resins Following Immersion in...Med Sci Monit In Press; DOI: 10.12659/MSM.946784
Clinical Research
Evaluation of Knowledge, Attitudes, and Practices Toward Thyroid Nodules in 456 Patients with Thyroid NodulesMed Sci Monit In Press; DOI: 10.12659/MSM.945732
Most Viewed Current Articles
17 Jan 2024 : Review article 6,966,841
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 701,694
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 25,087
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 19,746
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912